I dentification of novel genetic risk factors for venous thromboembolism has led thrombophilia to be considered a multigene disorder. However, thrombotic events in many thrombophilic families remain largely unexplained. The natural anticoagulant protein C/protein S (PC/PS) system contributes largely to the regulation of hemostasis. Thrombin binds to thrombomodulin (TM), an endothelial cell surface glycoprotein receptor, in a stoichiometric 1:1 complex that rapidly activates PC. 1 In the presence of its cofactor PS, activated PC degrades the clotting cofactors activated factors Va (FVa) and VIIIa (FVIIIa), thereby downregulating the coagulation cascade. The thrombin-TM complex is also involved in the physiological regulation of fibrinolysis by activating the recently discovered thrombin-activated fibrinolysis inhibitor. 2 Genetic defects in components of the PC/PS system are risk factors for venous thrombosis. This is the case of PC and PS gene mutations, as well as the FV Leiden mutation (which modifies the activated PC cleavage site at position 506 of FVa 3 ) and the prothrombin gene 20210G/A mutation associated with high levels of circulating prothrombin. 4 The TM gene is located on chromosome 20. It spans 6.1 kb and contains no introns. The sequences of the adjacent 5Ј-(2200 nucleotides) and 3Ј-flanking regions have been determined. [5] [6] [7] [8] Nine point mutations of the coding sequence (nucleotides 127G/A, 129G/C, 236G/C, 543G/A, 1418C/T, 1456G/T, 1483C/T, 1502C/T, and 1689 ins T) have been found in patients with venous or arterial thrombosis, 9 -11 but no clear association with thrombosis has been demonstrated. The promoter region contains several positive and negative regulatory elements for constitutive and modulated expression. 8, [12] [13] [14] [15] [16] Ohlin et al 9 recently studied the proximal promoter up to nucleotide Ϫ287 (numbering according to Yu et al 12 ) . No mutations were found in Ͼ300 patients with thromboembolism. Three mutations (nucleotides Ϫ133C/A, Ϫ33G/A, and Ϫ9 to Ϫ10 GG/AT) were found by Ireland et al 17 in 1, 1, and 3 subjects, respectively, among 104 patients with myocardial infarction. The Ϫ33G/A mutation was also found in 1 control. Interestingly, both Ϫ33G/A mutations were found in Asians, pointing to a polymorphic site in this population. This idea was recently confirmed by Li et al, 18 who found a 15% frequency of this mutation in Han Chinese subjects of Mongolian origin. Moreover, Li et al also found evidence that the GϪ33A mutation was significantly associated with coronary artery disease. In a recent case-control study of venous thromboembolism involving Ͼ200 patients and 300 healthy subjects of similar age and sex living in Paris (the Paris Thrombosis Study [PATHROS]), we also found the Ϫ33G/A mutation, but no other sequence variations of the proximal promoter were identified. The Ϫ33G/A mutation, albeit rare, was slightly more frequent in the patients (0.97%) than in the controls (0.25%). However, transient transfection experi-ments with unstimulated cultured endothelial cells failed to show a clear association between the Ϫ33G/A transition and gene expression. 19 The distal promoter of the TM gene (nucleotides Ϫ300 to Ϫ2052) has not yet been screened in patients with thromboembolism. This region contains a silencer element, 15 a putative shear stress-responsive element (SSRE), 20 and 4 retinoic acid response elements that could modulate TM promoter activity. 8 In the present study, we screened the entire TM promoter region (up to nucleotide Ϫ2052) in the PATHROS population for novel polymorphisms that could modify TM gene expression.
Methods

Subjects, Blood Sampling, and DNA Preparation
The study population consisted of 327 patients Ͻ61 years who had had at least 1 objectively diagnosed episode of deep venous thrombosis and/or pulmonary embolism and 398 controls of similar age and sex. The PATHROS study design has been described elsewhere. 19 Varicose veins of the lower limbs were diagnosed by physical examination. As expected, known genetic risk factors for thrombosis, the FV R506Q mutation and the prothrombin gene 20210G/A mutation, and oral contraceptive use (an acquired risk factor for thrombosis) were more frequent in the cases than in the controls (Table 1) . Venous blood (9 vol) was collected onto 0.129 mol/L trisodium citrate (1 vol), and DNA was isolated by the method described by Miller et al 21 and stored at 4°C. Plasma was stored at Ϫ30°C until analysis.
Plasma Studies
Coagulation activation markers (prothrombin fragment 1ϩ2 [F1ϩ2] and D-dimer) and soluble TM were assayed in plasma from control subjects by using the Enzygnost F1ϩ2 (Behring), Asserachrom D-Di (Diagnostica Stago), and Asserachrom TM (Diagnostica Stago) kits, respectively.
DNA Studies
For a mutation with an allele frequency of 5%, the likelihood of detecting at least 1 case of this mutation in a sample of 40 subjects is 95%. We therefore initially sequenced the TM promoter regions of the first 40 patients enrolled in PATHROS to establish the spectrum of "frequent" polymorphisms. We then used restriction site analysis to study the entire PATHROS population to determine whether venous thromboembolism was associated with the 3 novel mutations identified in the 40 subjects, namely, 2 frequent polymorphisms and 1 rare mutation at an interesting location.
Genomic DNA Studies
Direct Sequencing of the TM Promoter Region
The TM promoter region (up to nucleotide Ϫ2052) was screened for sequence variations by sequencing the 4 overlapping fragments: 101B/102B (nucleotides Ϫ2073 to Ϫ1465), PTM9/302 (nucleotides Ϫ1598 to Ϫ447), 301/302 (nucleotides Ϫ1049 to Ϫ466), and 401/402 (nucleotides Ϫ526 to ϩ55) after polymerase chain reaction (PCR) amplification. The PCR mixtures contained 500 ng of genomic DNA, 200 mol/L dNTPs (Pharmacia Biotech), 30 pmol of each primer, 1ϫ PCR buffer 1 (10 mmol/L Tris-HCl, 20 mmol/L KCl, pH 8.3) or 1ϫ PCR buffer 2 [166 mmol/L (NH 4 ) 2 SO 4 , 666 mmol/L Tris-HCl, 67 mol/L disodium EDTA, 100 mmol/L mercapto-2-ethanol, and 2 g/mL bovine serum albumin) and 1 U of Taq polymerase (Super Taq, ATGC Biotechnologie) in a final volume of 100 L. The sequences of the primers and the specific PCR conditions used to amplify each fragment are given in Table 2 .
Automated cycle sequencing of double-stranded DNA was performed with the ABI prism dye terminator cycle sequencing ready reaction kit (Perkin Elmer) according to the manufacturer's instructions. The primers used for sequencing were the same as those used for PCR, except for the PTM9/302 and 301/302 fragments. The primers used to sequence the PTM9/302 fragment were 201 and 202B (Table 2 ). For 301/302, the reverse sequencing primer was 302, and the forward sequencing primer was changed to 301B (5Ј -1034
CGAGCAAGTGGCGTTTCTATG
-1014 3Ј). The sequencing profiles were analyzed on an ABI prism 310 or 377 apparatus (Perkin Elmer).
Restriction Site Analysis
The novel TM promoter mutations identified by sequencing were verified by restriction site analysis, and the same method was then used to screen for these mutations in the entire study population. The sequences of the primers used for amplification are reported in Table  2 , together with the specific PCR conditions. The restriction enzymes used and the restriction profiles associated with these mutations are shown in Table 3 . For 2 mutations (Ϫ1084C/T and Ϫ1078/Ϫ1079 del CC), restriction sites were created in the amplified fragments by using modified primers (pTM StuI and pTM XcmI).
The GϪ33A mutation was screened for as previously described. 19 The nucleotide 1418 C/T common dimorphism in the TM gene, responsible for the Ala 455 Val mutation, 9 was also screened for by digestion after amplification of the region of interest with a primer modified to introduce a cleavage site for AflIII in the presence of a T at position 1418 (Table 2) .
Statistical Analysis
Data were analyzed by using SAS software (SAS Institute Inc). The frequencies of oral contraceptive use and of the FV Leiden and prothrombin gene G20210A mutations were compared between the cases and controls by using the 2 test. The 2 test was also used to test whether the genotype distributions in cases and controls were in Hardy-Weinberg equilibrium. Allele frequencies were deduced from genotype frequencies. Standard disequilibrium coefficients (⌬) were calculated by using likelihood methods.
Characteristics of cases heterozygous for the TM del TT mutation and those homozygous for the wild-type TM allele were compared by using Student's t test for age and mean follow-up since the first venous thrombosis, whereas the 2 test was used to compare the percentage of women, oral contraceptive use, type of venous thrombosis, and the presence of varicose veins, postthrombotic syndrome, and known genetic risk factors for thrombosis (FV Leiden, prothrombin gene G20210A mutation, and PC or PS deficiency). The few subjects homozygous for the TM del TT mutation were excluded from these analyses.
Logistic regression analysis was used to determine whether venous thrombosis, varicose veins, and a postthrombotic syndrome were related to the TM gene mutations, with and without adjustment for age and sex. Because of their small number, subjects homozygous for the mutations were combined with heterozygotes for these analyses. The effect of sex, age, and type of venous thrombosis was evaluated by repeating the same analyses in each group separately (men versus women, young versus old, spontaneous versus nonspontaneous venous thrombosis, and first versus recurrent venous thrombosis). ANOVA with adjustment for age, sex, and oral contraceptive use was used to evaluate the mean concentrations of soluble TM, F1ϩ2, and D-dimer by genotype of TM in controls. Differences with a probability value Ͻ0.05 were considered statistically significant.
Results
Comparison of the patients' TM promoter sequences with the sequence published by Dittman et al 8 showed 5 differences present in all of the sequences, namely, 2 nucleotide changes (the G at position Ϫ827 upstream of the transcription start site proposed by Yu et al 12 was replaced by a T, and the G at position Ϫ753 was replaced by a C) and 3 insertions of a G at positions Ϫ735, Ϫ730, and Ϫ701. These insertions thus change the numbering upstream of nucleotide Ϫ701. For clarity, nucleotides will hereafter be numbered as proposed by Yu et al, followed by the new numbering system in brackets and italics. The 40 DNA samples initially screened contained 7 substitutions in the TM promoter, namely, the previously identified nucleotide Ϫ33 G/A mutation and 6 novel substitutions located
[Ϫ1087] (C/T), and Ϫ797 [Ϫ800] (C/G). We also found 2 deletions of 2 nucleotides each at positions Ϫ1208/Ϫ1209 ([Ϫ1211/Ϫ1212], del TT) and Ϫ1078/Ϫ1079 ([Ϫ1081/Ϫ1082], del CC) ( Table 3 ). The sequence variations at positions Ϫ1748 [Ϫ1751] and Ϫ1208/Ϫ1209 [Ϫ1211/Ϫ1212] were frequent: the first was found in the heterozygous state in 10 patients and in the homozygous state in 3 patients, whereas the second was found in the heterozygous state in 11 patients. These variations were then screened for in the entire study population (Table 4) . 
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The other variations were rare, being found in the heterozygous state in 1 patient each. These rare variations did not modify or create consensus binding sequences for transcription factors and were unlikely to have functional consequences, except for the Ϫ1166 [Ϫ1169] G/A mutation, which modified the core binding sequence (GACGACC) of a putative SSRE. 20 For this reason, the only rare novel mutation screened for in the entire study population was Ϫ1166G/A ( Table 4) .
The 2 frequent sequence variations, Ϫ1748 [Ϫ1751] G/C and Ϫ1208/Ϫ1209 [Ϫ1211/Ϫ1212] del TT, and the Ϫ1166
[Ϫ1169] G-to-A transition were in Hardy-Weinberg equilibrium in both the controls and the cases. The mutated alleles were not more frequent in the patients than in the controls: the odds ratios (followed by their 95% confidence intervals) adjusted for age and sex were 0.90 (0.66 to 1. G-to-A mutations, respectively, suggesting that these mutations are not risk factors for thrombosis.
We then investigated whether these mutations influenced coagulation activation status by measuring activation markers (F1ϩ2 and D-dimer) in controls. We found significantly higher D-dimer levels in subjects with the Ϫ1748 [Ϫ1751] G/C mutation (Table 5 ). Nineteen percent of the patients investigated had varicose veins. As expected, varicose veins were significantly associated with thrombosis (Pϭ0.004) and the postthrombotic syndrome (PϽ0.001). Because varicose veins are characterized by disorganization of vessel wall structure, which might be associated with altered TM expression, we sought an association between varicose veins and the 3 mutations. Interestingly, patients with the del TT allele were more likely to have varicose veins of the lower limbs than were patients with the wild-type allele (33% vs 17%, Pϭ0.007). The relative risk of varicose veins associated with this mutation was 2.21 (1.11 to 4.38) after adjustment for age and sex. The other mutations had no significant effect. Patients with the del TT allele did not differ significantly from other patients with regard to demographic data, clinical characteristics, or known genetic risk factors for venous thrombosis (FV Leiden, prothrombin gene G20210A mutation, and PC or PS deficiency). The del TT mutation did not increase the risk of recurrent thrombosis or the postthrombotic syndrome in patients with varicose veins. Homozygotes
.05, trend test. n indicates number of controls.
To elucidate the association between the del TT mutation and varicose veins, we sought disequilibrium linkage with another mutation that truly modulates TM function. We therefore sequenced DNA from the 53 patients heterozygous for the del TT mutation to identify variations in the cAMPregulating element located in the 3Ј-untranslated region of the TM gene. 16 No mutations were found. We then screened the same subjects for the Ala 455 Val mutation in the DNA coding sequence, which was also a good candidate, being frequent 9 and located in a region of the TM protein putatively involved in proliferative functions. 22 Fifty-one (96%) of the 53 patients heterozygous for the del TT mutation were also heterozygous for the Ala 455 Val mutation, while the other 2 patients were homozygous for Ala 455 Val. These results suggested a tight linkage disequilibrium of the del TT mutation and the Ala 455 Val mutation. We then genotyped the entire study population for this mutation (Table 6 ) and confirmed the tight linkage of the 2 mutations in cases (⌬ϭ0.983) and controls (⌬ϭ0.895) (PϽ0.01). No effect of the del TT mutation on TM expression was found when soluble TM levels in control subjects were analyzed according to genotype.
Discussion
We found 8 novel sequence variations in the TM promoter of patients with venous thromboembolism. Six of the novel sequence variations were rare:
] del CC, and Ϫ797 [Ϫ800] C/G. Among them, the Ϫ1166 [Ϫ1169] G/A mutation modified the core binding sequence (GAGACC) of a putative SSRE. 20 Recent studies have shown that blood flow and the associated fluid shear stress cause morphological and functional changes in endothelial cells, including up-or downregulation of TM expression, [23] [24] [25] which could involve this SSRE. By impairing this action, the mutation might alter endothelial cell anticoagulant functions and create a thrombotic tendency. However, we found no relationship between this mutation and the risk of thrombosis in the entire PATHROS population (327 patients and 398 controls).
The other 2 novel mutations, Ϫ1748 [Ϫ1751] G/C and Ϫ1208/Ϫ1209 [Ϫ1211/Ϫ1212) del TT, were frequent. The Ϫ1748 [Ϫ1751] G/C mutation was located in a promoter region shown by Tazawa et al 15 to be responsible for positive transcription in transient transfection assays. Moreover, this mutation created a putative Sp1-like responsive element (C -1748 TCCGCGTC) with only 1 mismatch relative to the Sp1 binding consensus sequence (C/AC/TCCGC/AT/CT/CC/A). We found a significant association between the Ϫ1748 [Ϫ1751] G/C mutation and higher plasma D-dimer levels, but no association with the risk of venous thromboembolism.
The del TT mutation did not affect a known regulating element or create a binding sequence for known transcription factors. The del TT allele did not significantly influence levels of coagulation activation markers (F1ϩ2 or D-dimer) in controls, suggesting no direct influence of the del TT allele on thrombin generation. This concept was supported by the absence of any association between this mutation and the risk of thrombosis.
Interestingly, we found a significant association between the del TT allele and varicose veins in the cases of the PATHROS study. No such relationship was found with the other sequence variations. Because the PATHROS study was not designed to identify risk factors for varicose veins, we have no information on the distribution of del TT in controls according to their history of varicose veins.
The role of heredity in the development of varicose veins of the lower limbs has been raised many times in the literature, 26, 27 but no genetic risk factor had been firmly identified. Varicose veins are characterized by a disorganized state of the vessel wall structure, and blood stasis is involved in their development. 28, 29 Blood stasis provokes ischemia, thereby decreasing oxygen availability to the tissues. The effect of oxygen privation on endothelial function could be the starting point for a cascade of events leading to endothelial cell activation, profound changes in subendothelial structures with leukocyte infiltration, and proliferation of smooth muscle cells and qualitative and quantitative changes in their functions.
It is not clear how a mutation in the TM promoter could intervene in varicose vein formation. However, we know that TM is expressed on endothelial cells, 30 smooth muscle cells, 31 and leukocytes 32 (the functions of all 3 cell types are modified in varicose veins) and that hypoxia can quantitatively modulate TM expression 31, 33, 34 by mechanisms involving cAMP. 35, 36 Low intracellular cAMP levels downregulate TM expression at the surface of endothelial cells, 37 and a functional cAMP-responsive element has been located in the 3Ј-untranslated region of the human TM gene. 16 TM has been suggested to regulate cell functions, such as proliferation, through mechanisms independent of those regulating hemostasis. An antiproliferative effect of TM has been demonstrated in tumor cells from patients with malignant melanoma, and it has been suggested that the lectin and cytoplasmic domains of TM could be involved in this effect. 38 Conversely, TM expression might promote atherosclerosis through mitogenic activity on vascular smooth muscle cells, the epidermal growth factor-like domain of the protein possibly having a juxtacrine mechanism. 22 Indeed, this domain has been found to be mitogenic for a fibroblastic cell line. 39 The del TT mutation could have a direct or indirect effect on the level of TM expression at the surface of cells activated by hypoxia. It has been suggested that in healthy subjects, the soluble TM level might reflect the quantity of TM expressed on the endothelial surface. 40 There is also some evidence to support this hypothesis from a family study of the mutation 
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1689 ins T. 10 The del TT mutation was not associated with soluble TM levels in our control population. A direct effect of this mutation on the level of TM expression seems doubtful, because it does not create or modify a known regulating element. The del TT mutation might rather act in tight linkage disequilibrium with another mutation with functional consequences. Because this second mutation might be located in the cAMP-responsive element of the 3Ј-untranslated region, 16 we sequenced this region in all of the patients heterozygous for the del TT mutation but found no sequence variations. The second mutation could also be located in the epidermal growth factor or lectin domain of the protein, which have been implicated in cell proliferation. One polymorphism, a nucleotide 1418C/T change predicting an Ala 455 Val substitution, has been identified in the sixth epidermal growth factor-like module. The frequency of the Val allele was Ϸ20% (16% to 26%) in subjects from the Netherlands, Sweden, and North America. 9 In our study population, the frequency of the Val allele was 13% in cases and 18% in controls. It has been suggested that the C/T dimorphism could be neutral with respect to venous thrombophilia and that it might be involved in the pathogenesis of myocardial infarction, although the latter hypothesis remains to be confirmed. The observed association between the Val allele and the del TT allele should now be explored for its possible involvement in the development of varicose veins.
